ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Takeda Pharmaceutical Co., Ltd.

Business Summary

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2022 JPYUSD
Gross Profit2,043.63B18,186.20M
Operating income610,496M5,432.77M
Income before tax317,938M2,829.31M
Net income230,059M2,047.28M
Diluted EPS145.861.29
Dividends Per Share1801.60
Total Assets13,178.01B108,572.75M
Total liabilities7,494.49B61,746.62M
Total equity5,683.01B46,821.99M
Operating cash flow1,021.21B9,087.77M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 1,770.53B 2,097.22B 3,291.18B 3,197.81B 3,569.00B
Gross Profit 1,148.86B 1,275.55B 1,789.37B 1,798.37B 2,043.63B
Operating income 195,320M 218,686M 302,612M 447,610M 610,496M
Income before tax 217,205M 127,612M -60,754M 366,159M 317,938M
Net income 186,886M 135,192M 44,241M 376,005M 230,059M
EBITDA 377,447M 466,377M 886,261M 1,007.28B 1,193.64B
Diluted EPS 237.55 139.82 28.24 238.95 145.86
Dividends Per Share 180 180 180 180 180
Total Assets 4,106.46B 13,792.77B 12,821.09B 12,912.29B 13,178.01B
Total liabilities 2,089.05B 8,606.78B 8,093.60B 7,735.11B 7,494.49B
Total equity 1,997.42B 5,181.98B 4,723.48B 5,173.03B 5,683.01B
Operating cash flow 379,600M 302,609M 555,410M 905,073M 1,021.21B
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 15,974.84M 18,911.85M 30,270.54M 30,151.70M 31,760.44M
Gross Profit 10,365.80M 11,502.42M 16,457.72M 16,956.61M 18,186.20M
Operating income 1,762.30M 1,972.01M 2,783.25M 4,220.44M 5,432.77M
Income before tax 1,959.76M 1,150.74M -558.78M 3,452.46M 2,829.31M
Net income 1,686.20M 1,219.10M 406.90M 3,545.29M 2,047.28M
EBITDA 3,405.56M 4,205.58M 8,151.34M 9,497.50M 10,622.21M
Diluted EPS 2.14 1.26 0.25 2.25 1.29
Dividends Per Share 1.62 1.62 1.65 1.69 1.60
Total Assets 38,612.71M 124,612.85M 118,763.31M 116,853.33M 108,572.75M
Total liabilities 19,643.19M 77,759.25M 74,972.05M 70,001.05M 61,746.62M
Total equity 18,781.60M 46,817.41M 43,754.18M 46,814.81M 46,821.99M
Operating cash flow 3,424.99M 2,728.79M 5,108.35M 8,533.80M 9,087.77M

Valuation Measures

Mar 2022
Operating margin17.10%
Profit margin6.44%

Key executives

  • President, CEO & Representative Director: Christophe Weber
  • Chief Financial Officer & Director: Constantine Saroukos
  • Director, President-Research & Development: Andrew S. Plump
  • Chief Medical & Scientific Officer: Michael E. Mendelsohn
  • Chief Accounting Officer & Corporate Controller: Norimasa Takeda


  • Nomura Asset Management Co., Ltd. (4.2%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.8%)
  • BlackRock Fund Advisors (3.2%)
  • The Vanguard Group, Inc. (2.5%)
  • Nikko Asset Management Co., Ltd. (2.0%)
  • Daiwa Asset Management Co. Ltd. (1.9%)
  • Nippon Life Insurance Co. (1.8%)
  • Norges Bank Investment Management (1.4%)
  • BlackRock Japan Co., Ltd. (1.4%)
  • Takeda Pharmaceutical Co., Ltd. (1.3%)

Contact Details

Related Companies

  • Takeda Pharmaceutical Co. Ltd. /Life Science Park Ops/
  • Takeda Pharmaceutical Co Ltd /Asker Pharma Manufacturing Ops/
  • Takeda Digital Ventures
  • Takeda Pharmaceutical Co. Ltd. /5 Prescription Pharma Asset/
  • Takeda Pharmaceutical Employee Long Term Incentive Plan
  • Takeda Pharmaceutical Co. Ltd. /Prescription Pharma Ass
  • Takeda Dunboyne Biologics Ltd.
  • Plasmaspendedienst GmbH
  • Takeda Belgium NV
  • Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
  • Takeda Re Insurance AG
  • Plasmapunkt Favoriten GmbH
  • Takeda Malaysia Sdn. Bhd.
  • Takeda Pharmaceutical Co. Ltd. /Latam Bus/
  • Takeda Oranienburg Real Estate GmbH & Co. KG
  • Pvp Biologics, Inc.
  • Maverick Therapeutics, Inc.
  • Gammadelta Therapeutics Ltd.
  • Takeda Pharmaceutical Director Incentive Plan
  • Takeda Pharmaceutical Employee Incentive Plan
  • Oy Leiras Takeda Pharmaceuticals AB
  • Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
  • Takeda Pharma AB
  • Takeda Development Center Americas, Inc.
  • Takeda Ukraine LLC
  • Takeda Pharmaceuticals Taiwan Ltd.
  • Takeda SRL
  • Takeda Hellas SA
  • Takeda Christiaens SCA/CVA
  • Takeda Belgium SCA/CVA


  • AstraZeneca PLC
  • Grifols, S.A. Class A
  • Green Cross Corporation
  • Amgen Inc.
  • CSL Limited
  • Karyopharm Therapeutics, Inc.
  • Amicus Therapeutics, Inc.
  • Protalix Biotherapeutics, Inc.
  • ADMA Biologics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Sanofi
  • Mochida Pharmaceutical Co., Ltd.
  • AbbVie, Inc.
  • Merck & Co., Inc.
  • Organon & Co.
  • Roche Holding Ltd Dividend Right Cert.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Novo Nordisk A/S Class B
  • UCB S.A.
  • Merck KGaA
  • Swedish Orphan Biovitrum AB
  • JCR Pharmaceuticals Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Pharming Group NV
  • Oncopeptides AB
  • BioCryst Pharmaceuticals, Inc.
  • ISU Abxis Co., Ltd.
Last Updated on 27 Jan, 2023

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more